Published in J Antimicrob Chemother on September 18, 2010
The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol (2011) 1.86
Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol (2012) 1.69
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One (2013) 1.51
Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol Res Pract (2014) 1.02
Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii. Gut Microbes (2014) 0.96
Potential probiotic Kluyveromyces marxianus B0399 modulates the immune response in Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut microbiota in an in vitro colonic model system. Appl Environ Microbiol (2011) 0.93
Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis. Antimicrob Agents Chemother (2014) 0.92
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother (2012) 0.90
Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol (2011) 0.89
Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol (2015) 0.87
Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 0.86
Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota. Antimicrob Agents Chemother (2012) 0.84
Intestinal microbiome changes and stem cell transplantation: Lessons learned. Virulence (2016) 0.82
Integration of datasets from different analytical techniques to assess the impact of nutrition on human metabolome. Front Cell Infect Microbiol (2012) 0.81
Novel Polyfermentor intestinal model (PolyFermS) for controlled ecological studies: validation and effect of pH. PLoS One (2013) 0.80
Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Int J Mol Sci (2016) 0.79
Antibiotic Treatment Affects Intestinal Permeability and Gut Microbial Composition in Wistar Rats Dependent on Antibiotic Class. PLoS One (2015) 0.78
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol (2015) 0.77
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. Clin Transl Gastroenterol (2016) 0.75
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol (2016) 0.75
Comment on: Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother (2011) 0.75
Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol (2016) 0.75
Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial. BMC Vet Res (2016) 0.75
Management of covert hepatic encephalopathy. J Clin Exp Hepatol (2014) 0.75
Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther (2017) 0.75
Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time? Dig Dis Sci (2017) 0.75
The Role of Supplemental Complex Dietary Carbohydrates and Gut Microbiota in Promoting Cardiometabolic and Immunological Health in Obesity: Lessons from Healthy Non-Obese Individuals. Front Nutr (2017) 0.75
Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 14.12
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One (2010) 3.64
Prebiotic effects: metabolic and health benefits. Br J Nutr (2010) 3.49
Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut (2012) 3.09
Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol (2005) 2.18
New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol (2003) 1.88
Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res (2009) 1.57
Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol (2002) 1.56
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol (2003) 1.51
Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: an overview of enabling science and potential applications. FEMS Microbiol Ecol (2005) 1.50
Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology (2010) 1.48
Identification of prebiotic fructooligosaccharide metabolism in Lactobacillus plantarum WCFS1 through microarrays. Appl Environ Microbiol (2007) 1.48
Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol (2011) 1.46
Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med (2012) 1.45
PASSCLAIM--gut health and immunity. Eur J Nutr (2004) 1.43
Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol (2002) 1.41
Microbial-gut interactions in health and disease. Prebiotics. Best Pract Res Clin Gastroenterol (2004) 1.37
Unbalance of intestinal microbiota in atopic children. BMC Microbiol (2012) 1.37
Aging of the human metaorganism: the microbial counterpart. Age (Dordr) (2011) 1.36
Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr (2008) 1.34
Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. Br J Nutr (2007) 1.34
Mechanisms of probiosis and prebiosis: considerations for enhanced functional foods. Curr Opin Biotechnol (2009) 1.28
Intestinal microflora of human infants and current trends for its nutritional modulation. Br J Nutr (2002) 1.27
Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr (2007) 1.26
Gut microbiome modulates the toxicity of hydrazine: a metabonomic study. Mol Biosyst (2009) 1.24
Exopolysaccharides produced by Bifidobacterium longum IPLA E44 and Bifidobacterium animalis subsp. lactis IPLA R1 modify the composition and metabolic activity of human faecal microbiota in pH-controlled batch cultures. Int J Food Microbiol (2009) 1.20
Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radic Biol Med (2004) 1.19
A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) in healthy human subjects. Br J Nutr (2010) 1.18
Prebiotics and the health benefits of fiber: current regulatory status, future research, and goals. J Nutr (2012) 1.17
Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol (2007) 1.17
A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr (2013) 1.16
Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm Bowel Dis (2009) 1.16
Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis (2002) 1.15
An in vitro study of the probiotic potential of a bile-salt-hydrolyzing Lactobacillus fermentum strain, and determination of its cholesterol-lowering properties. Appl Environ Microbiol (2003) 1.15
Carbohydrate preferences of Bifidobacterium species isolated from the human gut. Curr Issues Intest Microbiol (2003) 1.15
Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol (2013) 1.14
Variation in antibiotic-induced microbial recolonization impacts on the host metabolic phenotypes of rats. J Proteome Res (2011) 1.13
Antimicrobial and antitumor activity of N-heteroimmine-1,2,3-dithiazoles and their transformation in triazolo-, imidazo-, and pyrazolopirimidines. Bioorg Med Chem (2002) 1.13
Monitoring of microbial metabolites and bacterial diversity in beef stored under different packaging conditions. Appl Environ Microbiol (2011) 1.12
High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum (2007) 1.12
Effect of a synbiotic food consumption on human gut metabolic profiles evaluated by (1)H Nuclear Magnetic Resonance spectroscopy. Int J Food Microbiol (2009) 1.12
Metabolic signatures of extreme longevity in northern Italian centenarians reveal a complex remodeling of lipids, amino acids, and gut microbiota metabolism. PLoS One (2013) 1.11
Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res (2012) 1.11
Flavanol monomer-induced changes to the human faecal microflora. Br J Nutr (2007) 1.11
Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr (2010) 1.11
Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr Opin Clin Nutr Metab Care (2014) 1.10
Impact of a synbiotic food on the gut microbial ecology and metabolic profiles. BMC Microbiol (2010) 1.10
Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res (2012) 1.09
In vitro investigations of the effect of probiotics and prebiotics on selected human intestinal pathogens. FEMS Microbiol Ecol (2002) 1.08
Differences in rDNA libraries of faecal bacteria derived from 10- and 25-cycle PCRs. Int J Syst Evol Microbiol (2002) 1.07
Different fecal microbiotas and volatile organic compounds in treated and untreated children with celiac disease. Appl Environ Microbiol (2009) 1.06
Iron-overload induces oxidative DNA damage in the human colon carcinoma cell line HT29 clone 19A. Mutat Res (2002) 1.06
Prebiotic capacity of inulin-type fructans. J Nutr (2007) 1.05
Microbiology of the human intestinal tract and approaches for its dietary modulation. Curr Pharm Des (2009) 1.05
Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host. Microbiology (2009) 1.04
DnaK from Bifidobacterium animalis subsp. lactis is a surface-exposed human plasminogen receptor upregulated in response to bile salts. Microbiology (2010) 1.03
Binding of human plasminogen to Bifidobacterium. J Bacteriol (2007) 1.02
Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr (2008) 1.02
High taxonomic level fingerprint of the human intestinal microbiota by ligase detection reaction--universal array approach. BMC Microbiol (2010) 1.01
Intestinal microbiota is a plastic factor responding to environmental changes. Trends Microbiol (2012) 1.00
Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res Microbiol (2005) 1.00
Pectin and pectic-oligosaccharides induce apoptosis in in vitro human colonic adenocarcinoma cells. Anticancer Res (2003) 0.99
Metabolism of anthocyanins by human gut microflora and their influence on gut bacterial growth. J Agric Food Chem (2012) 0.99
Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol (2010) 0.99
Functional intestinal microbiome, new frontiers in prebiotic design. Int J Food Microbiol (2010) 0.98
Probiotics and prebiotics: prospects for public health and nutritional recommendations. Ann N Y Acad Sci (2014) 0.98
A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. Br J Nutr (2011) 0.98
Carbohydrate preference, acid tolerance and bile tolerance in five strains of Bifidobacterium. J Appl Microbiol (2006) 0.98
Effect of a pre-treatment of milk with high pressure homogenization on yield as well as on microbiological, lipolytic and proteolytic patterns of "Pecorino" cheese. Int J Food Microbiol (2008) 0.98
Acid stress-mediated metabolic shift in Lactobacillus sanfranciscensis LSCE1. Appl Environ Microbiol (2011) 0.98
Probiotics and prebiotics in infant nutrition. Proc Nutr Soc (2007) 0.97
In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe (2012) 0.97
In vitro fermentation of carbohydrates by porcine faecal inocula and their influence on Salmonella Typhimurium growth in batch culture systems. FEMS Microbiol Ecol (2008) 0.97
Digestive and physiologic effects of a wheat bran extract, arabino-xylan-oligosaccharide, in breakfast cereal. Nutrition (2012) 0.96
Effect of lactose on gut microbiota and metabolome of infants with cow's milk allergy. Pediatr Allergy Immunol (2012) 0.96